A coherent research and development (R&D) plan to effectively and efficiently move compounds into multicenter efficacy trials for cocaine addiction pharmacotherapy does not exist at present. In light of this, in 1992, the Medications Development Division (MDD) of the National Institute of Drug Abuse (NIDA) sponsored three Clinical Decision Network workshops to identify, investigate, and develop actions that would facilitate the development of such a plan. From the first workshop, it was identified that the key missing element is the lack of a clinical decision tree that provided guidance in critical decision making regarding the selection, prioritizing, and discontinuation/ elimination of compounds from R&D process. In subsequent workshops (held on November 13, 1992) proposals were reviewed to address these issues, and a clinical decision tree (see figure 1) was developed with the following key features: (1) an assumption that the investigational compounds are with or without a strong clinical pharmacology model (table 1); (2) if the compound has a strong clinical pharmacology model, then development rationale, in initial safety, pharmacokinetics, and interaction with abused substances may be tested in human laboratory settings (table 2) , if not other proper hypothesisgenerating trials; and (3) for all compounds, the efficacy confirmation trials may be tested with designs specific to the proposed indication (table 3) .
